List of bibliographic references
Number of relevant bibliographic references: 8.
| Ident. | Authors (with country if any) | Title |
|---|
| 000729 (2016) |
Jeffrey H. Lipton [Canada] ; Charles Chuah [Singapour] ; Agnès Guerci-Bresler [France] ; Gianantonio Rosti [Italie] ; David Simpson [Nouvelle-Zélande] ; Sarit Assouline [Canada] ; Gabriel Etienne [France] ; Franck E. Nicolini [France] ; Philipp Le Coutre [Allemagne] ; Richard E. Clark [Royaume-Uni] ; Leif Stenke [Suède] ; David Andorsky [États-Unis] ; Vivian Oehler [États-Unis] ; Stephanie Lustgarten [États-Unis] ; Victor M. Rivera [États-Unis] ; Timothy Clackson [États-Unis] ; Frank G. Haluska [États-Unis] ; Michele Baccarani [Italie] ; Jorge E. Cortes [États-Unis] ; François Guilhot [France] ; Andreas Hochhaus [Allemagne] ; Timothy Hughes [Australie] ; Hagop M. Kantarjian [États-Unis] ; Neil P. Shah [États-Unis] ; Moshe Talpaz [États-Unis] ; Michael W. Deininger [États-Unis] | Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. |
| 002071 (2009) |
Michele Baccarani [Italie, Royaume-Uni, Espagne, Suisse, France, États-Unis, Australie, Suède, Allemagne] ; Jorge Cortes ; Fabrizio Pane ; Dietger Niederwieser ; Giuseppe Saglio ; Jane Apperley ; Francisco Cervantes ; Michael Deininger ; Alois Gratwohl ; François Guilhot ; Andreas Hochhaus ; Mary Horowitz ; Timothy Hughes ; Hagop Kantarjian ; Richard Larson ; Jerald Radich ; Bengt Simonsson ; Richard T. Silver ; John Goldman ; Rudiger Hehlmann | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet |
| 002197 (2008) |
Francis J. Giles [États-Unis] ; Daniel J. Deangelo [États-Unis] ; Michele Baccarani [Italie] ; Michael Deininger [États-Unis] ; Francois Guilhot [France] ; Timothy Hughes [Australie] ; Michael Mauro [États-Unis] ; Jerald Radich [États-Unis] ; Oliver Ottmann [Allemagne] ; Jorge Cortes [États-Unis] | Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia |
| 002200 (2008) |
Philipp Le Coutre [Allemagne] ; Oliver G. Ottmann [Allemagne] ; Francis Giles [États-Unis] ; Dong-Wook Kim [Corée du Sud] ; Jorge Cortes [États-Unis] ; Norbert Gattermann [Allemagne] ; Jane F. Apperley [Royaume-Uni] ; Richard A. Larson [États-Unis] ; Elisabetta Abruzzese [Italie] ; Stephen G. O'Brien [Royaume-Uni] ; Kazimierz Kuliczkowski [Pologne] ; Andreas Hochhaus [Allemagne] ; Francois-Xavier Mahon [France] ; Giuseppe Saglio [Italie] ; Marco Gobbi [Italie] ; Yok-Lam Kwong [Hong Kong] ; Michele Baccarani [Italie] ; Timothy Hughes [Australie] ; Giovanni Martinelli [Italie] ; Jerald P. Radich [États-Unis] ; MING ZHENG [États-Unis] ; YAPING SHOU [États-Unis] ; Hagop Kantarjian [États-Unis] | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia |
| 002216 (2008) |
Neil P. Shah [États-Unis, Corée du Sud, France, Brésil, Argentine, Mexique, Russie, Australie, Allemagne] ; Hagop M. Kantarjian ; Dong-Wook Kim ; Delphine Rea ; Pedro E. Dorlhiac-Llacer ; Jorge H. Milone ; Jorge Vela-Ojeda ; Richard T. Silver ; H. Jean Khoury ; Aude Charbonnier ; Nina Khoroshko ; Ronald L. Paquette ; Michael Deininger ; Robert H. Collins ; Irma Otero ; Timothy Hughes ; Eric Bleickardt ; Lewis Strauss ; Stephen Francis ; Andreas Hochhaus | Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia |
| 002541 (2006) |
Timothy Hughes [Australie, États-Unis, Allemagne, Royaume-Uni, Italie, France, Canada] ; Michael Deininger ; Andreas Hochhaus ; Susan Branford ; Jerald Radich ; Jaspal Kaeda ; Michele Baccarani ; Jorge Cortes ; Nicholas C. P. Cross ; Brian J. Druker ; Jean Gabert ; David Grimwade ; Rüdiger Hehlmann ; Suzanne Kamel-Reid ; Jeffrey H. Lipton ; Janina Longtine ; Giovanni Martinelli ; Giuseppe Saglio ; Simona Soverini ; Wendy Stock ; John M. Goldman | Monitoring CML patients responding to treatment with tyrosine kinase inhibitors : review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results |
| 002571 (2006) |
Michele Baccarani [Italie, États-Unis, Allemagne, Suède, Royaume-Uni, Espagne, Suisse, France, Australie] ; Giuseppe Saglio ; John Goldman ; Andreas Hochhaus ; Bengt Simonsson ; Frederick Appelbaum ; Jane Apperley ; Francisco Cervantes ; Jorge Cortes ; Michael Deininger ; Alois Gratwohl ; Francois Guilhot ; Mary Horowitz ; Timothy Hughes ; Hagop Kantarjian ; Richard Larson ; Dietger Niederwieser ; Richard Silver ; Rudiger Hehlmann | Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet |
| 002818 (2003) |
Stephen G. O'Brien [Royaume-Uni, France, États-Unis, Suisse, Italie, Espagne, Pays-Bas, Allemagne, Australie, Suède] ; Francois Guilhot ; Richard A. Larson ; Insa Gathmann ; Michele Baccarani ; Francisco Cervantes ; Jan J. Cornelissen ; Thomas Fischer ; Andreas Hochhaus ; Timothy Hughes ; Klaus Lechner ; Johan L. Nielsen ; Philippe Rousselot ; Josy Reiffers ; Giuseppe Saglio ; John Shepherd ; Bengt Simonsson ; Alois Gratwohl ; John M. Goldman ; Hagop Kantarjian ; Kerry Taylor ; Gregor Verhoef ; Ann E. Bolton ; Renaud Capdeville ; Brian J. Druker | Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 5 | Human |
| 4 | Chronic myelogenous leukemia |
| 3 | Antineoplastic agent |
| 3 | Cancerology |
| 3 | Chronic myelocytic leukemia |
| 3 | Imatinib |
| 3 | Protein-tyrosine kinase |
| 2 | Chronic |
| 2 | Clinical management |
| 2 | Enzyme inhibitor |
| 2 | Europe |
| 2 | Hybrid gene |
| 2 | Philadelphia chromosome |
| 2 | Resistance |
| 2 | Treatment efficiency |
| 1 | Abnormal chromosome C9 |
| 1 | Abnormal chromosome G22 |
| 1 | Adolescent |
| 1 | Adult |
| 1 | Advanced stage |
| 1 | Aged |
| 1 | Aged, 80 and over |
| 1 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 1 | C-Onc gene |
| 1 | Chemotherapy |
| 1 | Chromosome translocation |
| 1 | Chronic disease |
| 1 | Cohort study |
| 1 | Cytarabine |
| 1 | Daily dose |
| 1 | Dasatinib |
| 1 | Diagnosis |
| 1 | Disease-Free Survival |
| 1 | Drug combination |
| 1 | Drug-Related Side Effects and Adverse Reactions (classification) |
| 1 | Drug-Related Side Effects and Adverse Reactions (pathology) |
| 1 | Female |
| 1 | Fusion Proteins, bcr-abl (genetics) |
| 1 | Fusion protein |
| 1 | Gene expression |
| 1 | Hematology |
| 1 | Hematopoietic cell |
| 1 | Homograft |
| 1 | Humans |
| 1 | Imatinib Mesylate (administration & dosage) |
| 1 | Imatinib Mesylate (adverse effects) |
| 1 | Imidazoles (administration & dosage) |
| 1 | Imidazoles (adverse effects) |
| 1 | Interferon |
| 1 | Kaplan-Meier Estimate |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy) |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics) |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (pathology) |
| 1 | Low dose |
| 1 | Male |
| 1 | Middle Aged |
| 1 | Minimal residual disease |
| 1 | Multicenter study |
| 1 | Nilotinib |
| 1 | Non-specific serine/threonine protein kinase |
| 1 | Phase III trial |
| 1 | Philadelphia Chromosome (drug effects) |
| 1 | Polymerase chain reaction |
| 1 | Posology |
| 1 | Prognosis |
| 1 | Protein inhibitor |
| 1 | Pyridazines (administration & dosage) |
| 1 | Pyridazines (adverse effects) |
| 1 | Pyrimidine nucleoside |
| 1 | Real time |
| 1 | Recommendation |
| 1 | Review |
| 1 | Secondary effect |
| 1 | Stem cell |
| 1 | Surveillance |
| 1 | Targeting |
| 1 | Therapeutic protocol |
| 1 | Tolerance |
| 1 | Treatment |
| 1 | Treatment Outcome |
| 1 | Tyrosine kinase inhibitor |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Timothy Hughes"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Timothy Hughes" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Timothy Hughes
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
